Literature DB >> 26598017

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.

E Hoster1,2, C H Geisler3, J Doorduijn4, B van der Holt5, J Walewski6, J Bloehdorn7, V Ribrag8, G Salles9, M Hallek10, C Pott11, M Szymczyk6, A Kolstad12, A Laurell13, R Räty14, M Jerkeman15, M Van't Veer4, J C Kluin-Nelemans16, W Klapper17, M Unterhalt1, M Dreyling1, O Hermine18,19.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26598017     DOI： 10.1038/leu.2015.322

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Mats Jerkeman; Riikka Räty; Niels S Andersen; Lone B Pedersen; Mikael Eriksson; Marie Nordström; Eva Kimby; Hans Bentzen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Mats Ehinger; Christer Sundström; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Br J Haematol       Date:  2012-05-29       Impact factor: 6.998

3.  Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.

Authors:  Eva Hoster; Wolfram Klapper; Olivier Hermine; Hanneke C Kluin-Nelemans; Jan Walewski; Achiel van Hoof; Marek Trneny; Christian H Geisler; Francesco Di Raimondo; Michal Szymczyk; Stephan Stilgenbauer; Catherine Thieblemont; Michael Hallek; Roswitha Forstpointner; Christiane Pott; Vincent Ribrag; Jeanette Doorduijn; Wolfgang Hiddemann; Martin H Dreyling; Michael Unterhalt
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

4.  The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.

Authors:  S Robinson; P Dreger; D Caballero; P Corradini; C Geisler; M Ghielmini; S Le Gouill; E Kimby; S Rule; U Vitolo; M Dreyling; O Hermine
Journal:  Leukemia       Date:  2014-07-18       Impact factor: 11.528

5.  ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.

Authors:  M Dreyling; C Thieblemont; A Gallamini; L Arcaini; E Campo; O Hermine; J C Kluin-Nelemans; M Ladetto; S Le Gouill; E Iannitto; S Pileri; J Rodriguez; N Schmitz; A Wotherspoon; P Zinzani; E Zucca
Journal:  Ann Oncol       Date:  2013-02-20       Impact factor: 32.976

6.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Niels S Andersen; Lone B Pedersen; Mats Jerkeman; Mikael Eriksson; Marie Nordström; Eva Kimby; Anne Marie Boesen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Måns Akerman; Mats Ehinger; Christer Sundström; Ruth Langholm; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

7.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.

Authors:  Eva Hoster; Martin Dreyling; Wolfram Klapper; Christian Gisselbrecht; Achiel van Hoof; Hanneke C Kluin-Nelemans; Michael Pfreundschuh; Marcel Reiser; Bernd Metzner; Hermann Einsele; Norma Peter; Wolfram Jung; Bernhard Wörmann; Wolf-Dieter Ludwig; Ulrich Dührsen; Hartmut Eimermacher; Hannes Wandt; Joerg Hasford; Wolfgang Hiddemann; Michael Unterhalt
Journal:  Blood       Date:  2007-10-25       Impact factor: 22.113

8.  High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.

Authors:  Mars B van 't Veer; Daphne de Jong; Marius MacKenzie; Hanneke C Kluin-Nelemans; Marinus H J van Oers; Jose Zijlstra; Anton Hagenbeek; Wim L J van Putten
Journal:  Br J Haematol       Date:  2008-11-26       Impact factor: 6.998

9.  Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?

Authors:  Pierre Peterlin; Christophe Leux; Thomas Gastinne; Virginie Roland; Béatrice Mahé; Viviane Dubruille; Jacques Delaunay; Patrice Chevallier; Thierry Guillaume; Nicolas Blin; Sameh Ayari; Aline Clavert; Mohamad Mohty; Christelle Dousset; Noel Milpied; Jean Luc Harousseau; Philippe Moreau; Soraya Wuilleme; Anne Moreau; Steven Le Gouill
Journal:  Transplantation       Date:  2012-08-15       Impact factor: 4.939
  9 in total
  3 in total

1.  Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival.

Authors:  Ingrid Glimelius; Karin E Smedby; Alexandra Albertsson-Lindblad; Michael J Crowther; Sandra Eloranta; Mats Jerkeman; Caroline E Weibull
Journal:  Blood Adv       Date:  2021-03-23

Review 2.  Hematopoietic cell transplantation for mantle cell lymphoma.

Authors:  Masamitsu Yanada; Kazuhito Yamamoto
Journal:  Int J Hematol       Date:  2022-01-29       Impact factor: 2.490

3.  Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.

Authors:  Jeanette K Doorduijn; Josee M Zijlstra; Pieternella J Lugtenburg; Marie Josee Kersten; Lara H Böhmer; Monique C Minnema; Marius A MacKenzie; Rien van Marwijk Kooij; Eva de Jongh; Tjeerd J F Snijders; Okke de Weerdt; Michel van Gelder; Mels Hoogendoorn; Rineke B L Leys; Robby E Kibbelaar; Daphne de Jong; Dana A Chitu; Mars B Van't Veer; Hanneke C Kluin-Nelemans
Journal:  Br J Haematol       Date:  2020-03-09       Impact factor: 6.998
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.